Patient Guide: Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

We'll Help You Connect with This Trial

Quri.ai is a free clinical trial matching service. We help patients like you connect directly with research sites conducting this study.

  • Get matched to the right study location for you
  • Connect directly with study coordinators at 271 participating sites
  • Understand eligibility with our simplified screening tool
  • Free service - we're here to help you access clinical research
Trial ID: NCTNCT06357533
Status: 🟢 Enrolling Now
Condition: Non-Small Cell Lung Cancer
Phase: PHASE3

Find a Study Location Near You

This study is available at 271 research sites. We'll help you connect with the location that's right for you.

Participating sites include:
  • Anchorage, Alaska
  • Tucson, Arizona
  • Little Rock, Arkansas
  • • And 268 more locations - let us help you find the closest one

Loading interactive enrollment tools...

The full interactive experience will load momentarily